GO
Loading...

Pharmaceuticals

More

  • Genentech: Is Bottom Line Pushing Use of Lucentis? Friday, 12 Oct 2007 | 4:11 PM ET

    It didn't take long. Yesterday, I blogged that I'd be curious to hear what the response of doctors might be to Genentech's new crackdown on the use of Avastin instead of Lucentis for age-related macular degeneration. Today, the American Academy of Opthamology put out a press release saying the new policy "could have a significant impact on the care of patients with (AMD)."

  • Genentech: Did I Bury The Lead About Avastin? Friday, 12 Oct 2007 | 11:27 AM ET

    Yesterday I reported that Genentech had quietly buried on its web site www.gene.com the announcement of its new crackdown against using Avastin instead of Lucentis for adult-onset blindness. From the homepage, I had counted four somewhat counterintuitive clicks to get the link to the letter detailing the new policy.

  • Shortly after writing my last blog entry on Genentech's new ranking and part of the reason for its fall being blamed on the Lucentis/Avastin eye drug controversy, I came across this news item on The Wall Street Journal's Health Blog.

  • Stop Trading!: Amgen's Attractive Thursday, 11 Oct 2007 | 3:36 PM ET

    If the pharma company wins its lawsuit with Roche, investors could do very well with this stock.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Genentech Drops In (Industry) Poll, New Number One! Thursday, 11 Oct 2007 | 2:22 PM ET

    What a week for upsets. First, the 35-game home field winning streak of my USC Trojans comes to an end at the hands of the 40-point underdog Stanford Cardinal. Then, today, Genentech's six-year reign at the top of a big industry survey is over. Boehringer Ingelheim is the new number one!

  • Medtronic: The Cents of Making Stents Thursday, 11 Oct 2007 | 10:42 AM ET

    Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.

  • On the Line: BioMarin Pharma's CEO Jean Jacques Bienaime Thursday, 11 Oct 2007 | 10:38 AM ET

    The company should be profitable next year, the chief executive said, thanks to the expected approval of a new drug.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Your Health, Your Trade Wednesday, 10 Oct 2007 | 11:01 PM ET

    BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).

  • Glaxo Buys into Synta, Investors Sell Wednesday, 10 Oct 2007 | 1:08 PM ET

    Melanoma -- a type of skin cancer -- is the most common form of cancer. It can spread very quickly and the prognosis often is not good. The American Cancer Society estimates that nearly 60,000 new cases of melanoma will be diagnosed this year and more than 8,000 patients will die. You can find out more about it on the ACS's website.

  • Big Biotech Earnings Surprise? Genentech & Amgen Tuesday, 9 Oct 2007 | 11:01 AM ET

    As we head into the thick of earnings season some analysts are putting out their preview notes for clients. And a couple of interesting ones about the kings of biotech, Genentech and Amgen, have come into my inbox over the past couple of days. Genentech reports after the bell next Monday, October 15. And Amgen comes out, also after the bell, ten days later on the 25th.

  • Comings & Goings at Pfizer & Glaxo Monday, 8 Oct 2007 | 1:30 PM ET

    This morning, the world's second biggest drug company, GlaxoSmithKline, announced that Andrew Witty will replace JP Garnier as CEO at the end of next May. It's been known for a while that Garnier would be retiring next year, and the question was who would be tapped to succeed him.

  • Glaxo Names European Head, Witty, as New CEO Monday, 8 Oct 2007 | 3:20 AM ET

    GlaxoSmithKline has picked Andrew Witty, currently president of its European pharmaceuticals business, to succeed Chief Executive Jean-Pierre Garnier from May 2008, it said on Monday.

  • Ultrasound Drugs Face FDA Warning: WSJ Sunday, 7 Oct 2007 | 11:14 PM ET

    The U.S. Food and Drug Administration is preparing to warn physicians about hazards with drugs that use ultrasound imaging machines to enhance the diagnosis of heart problems, the Wall Street Journal reported on its Web site on Sunday.

  • As recession fears recede, investors show an increasing willingness to bet on another interest rate cut from the Federal Reserve.

  • Early Detection Trade Friday, 5 Oct 2007 | 4:17 PM ET

    It's a trade we told you about earlier this year. The rising cost of health care has sparked new interest in the early detection of diseases. We may have gotten a few such breakthroughs Thursday.

  • Cepheid: The Google of Biotech? Friday, 5 Oct 2007 | 2:08 PM ET

    This morning Bear Stearns put a $700 price target on shares of Google. But that's not the only stock getting a new stratospheric price target by an analyst. Michael Shulman is not Bear Stearns--he writes a newsletter for subscribers called, "ChangeWave Biotech Investor" and he maintains a blog. And in his weekly message yesterday Shulman moved his price target on Cepheid spacer from $40 to $110.

  • Fund Manager Picks Biotech, Pharma Stocks Friday, 5 Oct 2007 | 11:44 AM ET

    Scott Richter, portfolio manager with Fifth Third Asset Management, oversees the Fifth Third Disciplined Large Cap Value Fund. The fund is up 8 percent year-to-date and 13 percent over the last three years. The strategist offered CNBC viewers and CNBC.com readers a few of his favorite stocks in the health care and biotechnology sector.

  • Pfizer's Inside R&D Move: Are Investors Buying It? Thursday, 4 Oct 2007 | 1:25 PM ET

    Close on the heels of announcing the hiring of a Chief Talent Officer, Pfizer this morning named a new head of Global Research and Development to replace John LaMattina who had earlier said he'd be leaving the drug company. It was on LaMattina's watch that Pfizer's next potential breakout blockbuster drug, torcetrapib for cholesterol, failed in a late-stage clinical trial.

  • Pfizer's Got Talent! (Auditions In A City Near You) Wednesday, 3 Oct 2007 | 10:39 AM ET

    Pfizer put out a press release this morning announcing that it has added another office in the C-Suite. The world's biggest drug company has hired a CTO. What's a CTO, you ask?? Well, it doesn't stand for what you might guess--Chief Technology Officer. Nope, Pfizer has created the position of Chief Talent Officer.

  • Tylenol And The Thalidomide Scares: Moving Forward Tuesday, 2 Oct 2007 | 4:35 PM ET
    Old and new bottles of Tylenol products.

    This week it's 25 years since the first of seven people in Chicagoland died after taking Tylenol laced with cyanide. The scare led to new industry-standard, tamper-resistant over-the-counter drug packaging and became an enduring textbook case for corporate crisis management.